HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

Treatment of secondary hyperparathyroidism in patients on maintenance hemodialysis.

Abstract
The effects of CaCO3 were investigated in 7 patients undergoing maintenance hemodialysis who had been treated with 1 microgram/day 1 alpha (OH)D3 and 2 g/day Al(OH)3. CaCO3 (3 g/day) was administered instead of Al(OH)3. The levels of serum total calcium and ionized calcium were significantly increased, the level of C-terminal parathyroid hormone was appreciably decreased and the levels of serum aluminum in all patients were reduced. There were no significant changes in the levels of serum phosphate, calcium x phosphate product, alkaline phosphatase, calcitonin, magnesium and bicarbonate. It is concluded that 3 g/day CaCO3 is equivalent to 2 g/day Al(OH)3 in terms of its phosphate-binding effect, and the prescription of CaCO3 together with 1 alpha (OH)D3 ameliorates secondary hyperparathyroidism.
AuthorsK Okada, S Takahashi, Y Nagura, M Hatano
JournalNihon Jinzo Gakkai shi (Nihon Jinzo Gakkai Shi) Vol. 31 Issue 10 Pg. 1085-9 (Oct 1989) ISSN: 0385-2385 [Print] JAPAN
PMID2615019 (Publication Type: Journal Article)
Chemical References
  • Aluminum Hydroxide
  • Calcium Carbonate
Topics
  • Adult
  • Aged
  • Aluminum Hydroxide (therapeutic use)
  • Calcium Carbonate (therapeutic use)
  • Female
  • Humans
  • Hyperparathyroidism, Secondary (drug therapy, etiology)
  • Male
  • Middle Aged
  • Renal Dialysis (adverse effects)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: